Difference between revisions of "Insulin"
(New page: {{Subst:infobox}}) |
m |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| − | | align="center" colspan="2" bgcolor="#ffffff" | [[Image: | + | | align="center" colspan="2" bgcolor="#ffffff" | [[Image:Insulin.JPG|200px|{{PAGENAME}}]] |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 12: | Line 11: | ||
|- | |- | ||
| Determination type | | Determination type | ||
| − | | In | + | | In vitro |
|- | |- | ||
| Source | | Source | ||
| Line 18: | Line 17: | ||
|- | |- | ||
| Subcellular localization | | Subcellular localization | ||
| − | | | + | | Extracellular; plasma |
|- | |- | ||
| Swissprot ID | | Swissprot ID | ||
| Line 24: | Line 23: | ||
|- | |- | ||
| Reactive glutamines | | Reactive glutamines | ||
| − | | [[ | + | | [[TG2 reactive residues (Insulin)|chain A - Q5, Q15]] |
| + | [[TG2 reactive residues (Insulin)|chain B - Q4]] | ||
|- | |- | ||
| Reactive lysines | | Reactive lysines | ||
| − | | | + | | - |
|- | |- | ||
| Substrate sequence | | Substrate sequence | ||
| − | | | + | | chain A - GIVE''Q''C*C*ASVC*SLY''Q''LENYC*N |
| + | chain B - FVN''Q''HLC*GS | ||
| + | |||
|- | |- | ||
| Structure | | Structure | ||
| − | | [http://www.rcsb.org/pdb/explore/explore.do?structureId= | + | | [http://www.rcsb.org/pdb/explore/explore.do?structureId=1BEN 1BEN] |
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1ben.pdf ASAView] pdf |
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1ben.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
| Line 42: | Line 45: | ||
|- | |- | ||
| Reference | | Reference | ||
| − | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids= | + | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=14342319&dopt=Abstract PMID:14342319] |
|- | |- | ||
| Notes | | Notes | ||
| − | | | + | | * the Cys residues are oxidized |
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:45, 10 March 2015
| Insulin | |
|---|---|
| |
| Substrate peptide name | Insulin |
| Synonyms | - |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular; plasma |
| Swissprot ID | P08865 |
| Reactive glutamines | chain A - Q5, Q15 |
| Reactive lysines | - |
| Substrate sequence | chain A - GIVEQC*C*ASVC*SLYQLENYC*N
chain B - FVNQHLC*GS |
| Structure | 1BEN |
| Surface accessibility | ASAView pdf
ASAView txt |
| Disorder prediction | IUPred |
| Reference | PMID:14342319 |
| Notes | * the Cys residues are oxidized |
